ID   NY
AC   CVCL_1613
DR   CLO; CLO_0009877
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03471633
DR   cancercelllines; CVCL_1613
DR   Cell_Model_Passport; SIDM00569
DR   ChEMBL-Cells; CHEMBL3308123
DR   ChEMBL-Targets; CHEMBL1075552
DR   Cosmic; 910849
DR   Cosmic-CLP; 910849
DR   DepMap; ACH-002178
DR   EGA; EGAS00001000978
DR   GDSC; 910849
DR   GEO; GSM320822
DR   GEO; GSM827276
DR   GEO; GSM1670289
DR   IARC_TP53; 21591
DR   JCRB; JCRB0614
DR   LINCS_LDP; LCL-1429
DR   PharmacoDB; NY_1175_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1613
DR   PubChem_Cell_line; CVCL_1613
DR   Wikidata; Q54931209
RX   PubMed=6596455;
RX   PubMed=9290701;
RX   PubMed=15289353;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 21 days (Note=At 18th passage) (PubMed=6596455); ~60 hours (Note=Lot 091198), ~30 hours (Note=Lot 09262016) (JCRB=JCRB0614).
CC   HLA typing: A*26:01; B*55:02; C*03:03 (PubMed=15289353).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.02%; Native American=0.2%; East Asian, North=78.63%; East Asian, South=19.14%; South Asian=0.88%; European, North=0.59%; European, South=0.55% (PubMed=30894373).
CC   Derived from site: In situ; Bone, right femur; UBERON=UBERON_0000981.
ST   Source(s): Cosmic-CLP; JCRB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8
ST   D16S539: 10,13
ST   D5S818: 13
ST   D7S820: 11
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 18
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 33
//
RX   PubMed=6596455;
RA   Sekiguchi M., Asanuma K., Satomura T., Fukushima H., Fujji G.,
RA   Shimoda T., Fukunaga M., Ishikawa E.;
RT   "A cultured cell line established in vitro from human osteosarcoma.";
RL   Jpn. J. Exp. Med. 53:289-292(1983).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=15289353; DOI=10.1158/0008-5472.CAN-04-0522;
RA   Tsukahara T., Nabeta Y., Kawaguchi S., Ikeda H., Sato Y.,
RA   Shimozawa K., Ida K., Asanuma H., Hirohashi Y., Torigoe T., Hiraga H.,
RA   Nagoya S., Wada T., Yamashita T., Sato N.;
RT   "Identification of human autologous cytotoxic T-lymphocyte-defined
RT   osteosarcoma gene that encodes a transcriptional regulator,
RT   papillomavirus binding factor.";
RL   Cancer Res. 64:5442-5448(2004).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//